Gilead Sciences, Inc. (NASDAQ:GILD) Shares Bought by Railway Pension Investments Ltd

Railway Pension Investments Ltd grew its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 0.3% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,563,965 shares of the biopharmaceutical company’s stock after acquiring an additional 4,800 shares during the quarter. Railway Pension Investments Ltd owned about 0.13% of Gilead Sciences worth $114,560,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Financial Counselors Inc. lifted its position in Gilead Sciences by 1.5% in the fourth quarter. Financial Counselors Inc. now owns 8,862 shares of the biopharmaceutical company’s stock worth $718,000 after purchasing an additional 128 shares during the period. Steph & Co. lifted its position in Gilead Sciences by 1.9% in the fourth quarter. Steph & Co. now owns 7,548 shares of the biopharmaceutical company’s stock worth $611,000 after purchasing an additional 142 shares during the period. First Affirmative Financial Network lifted its position in Gilead Sciences by 3.5% in the first quarter. First Affirmative Financial Network now owns 4,342 shares of the biopharmaceutical company’s stock worth $318,000 after purchasing an additional 147 shares during the period. Rathbones Group PLC lifted its position in Gilead Sciences by 3.7% in the fourth quarter. Rathbones Group PLC now owns 4,185 shares of the biopharmaceutical company’s stock worth $339,000 after purchasing an additional 150 shares during the period. Finally, MCF Advisors LLC lifted its position in Gilead Sciences by 2.1% in the first quarter. MCF Advisors LLC now owns 7,348 shares of the biopharmaceutical company’s stock worth $538,000 after purchasing an additional 152 shares during the period. Institutional investors and hedge funds own 83.67% of the company’s stock.

Insider Transactions at Gilead Sciences

In other news, insider Merdad Parsey sold 2,000 shares of the business’s stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $68.63, for a total transaction of $137,260.00. Following the completion of the transaction, the insider now directly owns 96,380 shares in the company, valued at approximately $6,614,559.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 0.16% of the company’s stock.

Gilead Sciences Trading Up 0.4 %

Shares of Gilead Sciences stock traded up $0.28 during trading on Friday, hitting $76.77. 6,458,108 shares of the company were exchanged, compared to its average volume of 6,392,589. The firm has a market capitalization of $95.64 billion, a P/E ratio of 213.25, a price-to-earnings-growth ratio of 3.37 and a beta of 0.18. Gilead Sciences, Inc. has a 1-year low of $62.07 and a 1-year high of $87.86. The firm’s fifty day moving average price is $68.80 and its 200 day moving average price is $70.88. The company has a debt-to-equity ratio of 1.31, a current ratio of 1.08 and a quick ratio of 0.94.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the company. StockNews.com raised Gilead Sciences from a “buy” rating to a “strong-buy” rating in a report on Saturday, April 27th. Cantor Fitzgerald cut their price objective on Gilead Sciences from $75.00 to $70.00 and set a “neutral” rating for the company in a report on Monday, July 22nd. Morgan Stanley cut their price objective on Gilead Sciences from $80.00 to $78.00 and set an “equal weight” rating for the company in a report on Friday, April 26th. UBS Group cut their price objective on Gilead Sciences from $81.00 to $75.00 and set a “neutral” rating for the company in a report on Wednesday, April 17th. Finally, TD Cowen lowered their target price on Gilead Sciences from $90.00 to $85.00 and set a “buy” rating for the company in a research note on Friday, April 26th. Twelve analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $81.81.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.